scholarly journals Weakly hormone receptor– positive breast cancer and use of adjuvant hormonal therapy

2013 ◽  
Vol 20 (6) ◽  
pp. 612 ◽  
Author(s):  
C.M. Lin ◽  
J. Jaswal ◽  
T. Vandenberg ◽  
A. Tuck ◽  
M. Brackstone
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

2003 ◽  
Vol 1 (2) ◽  
pp. 215-221
Author(s):  
Jennifer A. Ligibel ◽  
Eric P. Winer
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitors ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Uterine Cancer ◽  
Adjuvant Hormonal Therapy ◽  
Adjuvant Setting ◽  
Modest Improvement ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Adjuvant hormonal therapy has been shown to decrease the risk of breast cancer recurrence and overall mortality in patients with hormone receptor-positive breast cancer. Tamoxifen has been used in this setting for many years, both in premenopausal and postmenopausal patients. Tamoxifen is not devoid of toxicity, and attempts have been made to develop newer hormonal agents with better efficacy and less toxicity. The aromatase inhibitors have shown equivalent or superior efficacy to tamoxifen in the treatment of metastatic breast cancer, and efforts are underway to determine the role of these agents in early breast cancer. The ATAC trial recently showed that use of the third-generation aromatase inhibitor anastrozole in the adjuvant setting led to a modest improvement in relapse-free survival as compared with tamoxifen. Patients treated with anastrozole were also less likely to develop uterine cancer or experience a thromboembolic event. However, patients treated with anastrozole were more likely than those treated with tamoxifen to suffer a fracture or other musculosketal problem. An ASCO technology assessment panel reviewed the relevant data and issued a consensus statement regarding the use of aromatase inhibitors in the adjuvant setting. In general, the panel favored the continued use of tamoxifen as adjuvant hormonal therapy for most postmenopausal women. Within the next few years, further data from the ATAC trial and from other trials of aromatase inhibitors in the adjuvant setting should be available to guide treatment recommendations for this patient population.

Abstract A52: Receipt of adjuvant hormonal therapy among Medicaid enrollees diagnosed with hormone-receptor positive breast cancer, 2004-2007.

2012 ◽  
Author(s):  
Tisha M. Felder ◽  
Lincy S. Lal ◽  
Dana Stafkey-Mailey ◽  
Phoenix Do ◽  
Kevin Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)

2012 ◽  
Vol 134 (1) ◽  
pp. 419-428 ◽  
Author(s):  
Alfred I. Neugut ◽  
Grace Clarke Hillyer ◽  
Lawrence H. Kushi ◽  
Lois Lamerato ◽  
Nicole Leoce ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Care ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Care Study ◽  
Positive Breast Cancer

Social support at diagnosis and noninitiation, discontinuation, and nonadherence to adjuvant hormonal therapy in the Pathways Study.

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 7-7 ◽  
Author(s):  
Candyce Kroenke ◽  
Dawn L. Hershman ◽  
Sara Adams ◽  
Marilyn L. Kwan ◽  
Lawrence H. Kushi
Keyword(s):  
Breast Cancer ◽  
Social Support ◽  
Cancer Patients ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Breast Cancer Patients ◽  
Positive Interaction ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

7 Background: Exceedingly little research has examined associations between social support and adherence to adjuvant hormonal therapy (AHT) in breast cancer patients. We evaluated associations of social support and noninitiation and discontinuation of, and nonadherence to, AHT in a large, Northern California cohort. Methods: This study included 3,382 women from the Pathways Study who were diagnosed with stages I-III hormone receptor positive breast cancer from 2006-2013 and responded to the Medical Outcomes Study social support survey approximately two months following diagnosis. We used logistic regression to evaluate associations between social support and noninitiation ( < 2 consecutive prescription fills within the first year after diagnosis). Among those who initiated treatment, we used proportional hazards regression to evaluate associations of social support, discontinuation ( > 90 day gap), and nonadherence ( < 80% medical possession ratio) to treatment. Results: Of those who initiated treatment (79%), approximately one fourth either discontinued AHT or were nonadherent. In multivariable-adjusted analyses, adjusted for sociodemographic characteristics, disease severity, other treatment, and presence of comorbidity, women with low (OR = 1.31, 95% CI: 1.06-1.62) and moderate (OR = 1.18, 95% CI: 0.96-1.46) levels of social support were more likely not to initiate AHT treatment, compared to those with high support. Emotional/informational support, tangible support, and positive interaction were each significantly related to noninitiation; affection was not. Of those who initiated treatment, women with low (HR = 1.30, 95% CI: 1.07-1.58) or moderate (HR = 1.19, 95% CI: 0.98-1.44) levels of support were more likely to discontinue treatment. Furthermore, women with low (HR = 1.37, 95% CI: 1.11-1.88) or moderate (HR = 1.24, 95% CI: 1.01-1.52) support had higher nonadherence to treatment. Conclusions: Hormone receptor positive breast cancer patients with low levels of social support had higher noninitiation and discontinuation of, and nonadherence to, AHT. Information on social support may help clinicians determine who is at greater risk of AHT nonadherence.

scholarly journals Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer

2011 ◽  
Vol 131 (2) ◽  
pp. 607-617 ◽  
Author(s):  
Jennifer C. Livaudais ◽  
Dawn L. Hershman ◽  
Laurel Habel ◽  
Lawrence Kushi ◽  
Scarlett Lin Gomez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ethnic Differences ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Racial Ethnic ◽  
Positive Breast Cancer

Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients

2020 ◽  
Vol 184 (3) ◽  
pp. 665-674
Author(s):  
Daqin Mao ◽  
Hilal Hachem ◽  
Hong Chang ◽  
Danai Dima ◽  
Joshua Dower ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Treatment Interruption ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document